{Etokimab: A Deep Examination into the 2022981-44-6 Protein Etokimab, designated by the specific identifier 2022981-44-6, represents a novel immunoglobulin currently subject to therapeutic evaluation. This medicinal https://www.targetmol.com/compound/etokimab